key: cord-0842315-64jfa90h authors: Schmidt, Débora; Piva, Taila Cristina; Glaeser, Sheila Suzana; Piekala, Daniele Martins; Berto, Paula Pinheiro; Friedman, Gilberto; Sbruzzi, Graciele title: Intensive Care Unit Acquired Weakness in Patients with COVID-19: Occurrence and Associated Factors date: 2022-03-01 journal: Phys Ther DOI: 10.1093/ptj/pzac028 sha: ac0d529f3358da117cdadb3ab2bdbc90276f7968 doc_id: 842315 cord_uid: 64jfa90h OBJECTIVE: The primary objective of this study was to identify the occurrence and factors associated with intensive care unit (ICU)–acquired weakness (ICUAW) in patients with COVID-19. Secondarily, we monitored the evolution of muscle strength and mobility among patients with ICUAW and patients without ICUAW and the association of these variables with length of stay, mechanical ventilation (MV), and other clinical variables. METHODS: In this prospective observational study, patients admitted to the ICU for >72 h with COVID-19 were evaluated for muscle strength and mobility at 3 times: when being weaned from ventilatory support, discharged from the ICU, and discharged from the hospital. Risk factors for ICUAW were monitored. RESULTS: The occurrences of ICUAW at the 3 times evaluated among the 75 patients included were 52%, 38%, and 13%. The length of the ICU stay (29.5 [16.3–42.5] versus 11 [6.5–16] days; P ≤ .001), the length of the hospital stay (43.5 [22.8–55.3] versus 16 [12.5–24] days; P ≤ .001) and time on MV (25.5 [13.8–41.3] versus 10 [5–22.5] days; P ≤ .001) were greater in patients with ICUAW. Muscle strength and mobility were lower at all times assessed in patients with ICUAW (P < .05). Bed rest time for all patients (relative risk = 1.14; 95% CI = 1.02–1.28; P = .03 per week) and use of corticosteroids (relative risk = 1.01; 95% CI = 1.00–1.03; P = .01 per day) for those who required MV were factors independently associated with ICUAW. Muscle strength was found to have a positive correlation with mobility and a negative correlation with lengths of stay in the ICU and hospital and time on MV. CONCLUSIONS: The occurrence of ICUAW was high upon patients’ awakening in the ICU but decreases throughout hospitalization; however, strength and mobility remained compromised at hospital discharge. Bed rest time and use of corticosteroids (for those who needed MV) were factors independently associated with ICUAW in patients with COVID-19. ICUAW is a common complication of critical illness, with an incidence of around 43%, varying according to the population studied, risk factors, timing and methods used for diagnosis. 7, 8 It is associated with an increase in mortality, a need for prolonged mechanical ventilation (MV), and a longer hospital stay. 9,10 A recent study including 12 patients with severe acute respiratory distress syndrome caused by SARS-CoV-2 and with muscle weakness and difficulty being weaned from MV showed that 11 patients had alterations in the neurophysiological study, 63.6% were compatible with critical myopathy, and 36.4% were compatible with neuropathy. 11 In another study with 50 patients who had COVID-19 and required invasive MV (IMV), 72% had ICUAW when awakening, 52% had ICUAW on discharge from the ICU, and 27% had ICUAW on discharge from the hospital. 12 Considering the importance of understanding the aspects involved in the development of ICUAW in patients with COVID-19, the primary objective of the present study was to identify the occurrence and factors associated with the development of ICUAW in patients hospitalized because of COVID-19. To accomplish this aim, we specifically examined the association between the development of ICUAW and the level of mobility, time on MV, length of hospital stay, length of ICU stay, rate of readmission to the ICU, and other clinical variables. We also monitored and compared the evolution of muscle strength and mobility during hospitalization among patients who developed ICUAW and those who did not. [H1]Methods This was a prospective observational study carried out in a COVID-19-specific ICU, from May to August 2020 and approved by the Research Ethics Committee of the Hospital de Clínicas de Porto Alegre (CAAE: 31080820.0.0000.5327). Patients who were older than 18 years of age, had confirmed SARS-CoV-2 infection (through a real-time reverse transcription-polymerase chain reaction), and required ICU admission for at least 72 hours were included in the study. Patients who had muscle weakness secondary to neurological or musculoskeletal disease prior to admission were excluded (information was obtained by reviewing the patients' medical records and interviewing their guardians at the time of obtaining authorization for inclusion in the study), as were those who were unable to communicate and follow the examiner's commands for the proposed assessments. Furthermore, patients who could not complete all of the proposed assessments were excluded from the comparison analysis over time. All patients included had their participation authorized by their guardians through an informed consent form, and patient consent was obtained at the moment of assessment (when the patient was awake). The patients were monitored daily by the researchers for clinical evolution and awakening. For assessments, the patient had to be calm, awake, and able to obey at least I P T 3 of the De Jonghe 5 command criteria (open and close your eyes; look at me; open your mouth and stick your tongue out; shake your head "yes"; raise your eyebrows when I count to 5). 13 The assessments were carried out by 4 physical therapists and researchers who had experience in the care of patients admitted to the ICU and who were previously trained to administer the assessment instruments. The assessments were carried out 3 times during the hospital stay. assessed when they tolerated reductions in the flow and oxygen concentration parameters, without the need to increase these parameters for at least 24 hours). Assessment 2 (ICU discharge) was performed up to 24 hours before ICU discharge. Assessment 3 (hospital discharge) was performed up to 24 hours before hospital discharge. The following outcomes were assessed in the 3 periods described above. Korea) with the elbow positioned at 90 degrees, The best result was considered for analysis and compared with the values predicted for the Brazilian population. 14 Mobility was assessed with the Perme Intensive Care Unit Mobility Score (Perme Score), which includes an assessment of mental status, potential barriers to mobility, functional strength, mobility in bed, transfers, assistive devices for walking, and resistance measures. The final score varies between 0 and 32 points, with a low score indicating more mobility barriers and greater need for assistance for mobilization. 15 The level of mobility was assessed with the ICU Mobility Scale, which consists of 11 mobility stages scored from 0 to 10, where 0 = lying in bed and 10 = independent walking without the aid of a walking device. 15 The following variables were also assessed: lengths of hospital stay and ICU stay; We used the Poisson regression model, initially performing univariable regression including variables that were investigated in previous studies as risk factors for ICUAW 6, 8, 9 . From that, factors that had P values of <.05 were added to a multivariable regression model. The relative risk and 95% CI were presented together with the P value. The Friedman test was used to compare variables (muscle strength and mobility) over time (assessments 1, 2, and 3). Correlations were assessed using the Spearman test; correlation coefficients between 0.9 and 1 were considered very strong, those from 0.7 to 0.89 were considered strong, and those from 0.5 to 0.69 were considered moderate. 16 For data analysis, the software Statistical Package for the Social Sciences, version 20.0 (IBM SPSS, Chicago, IL, USA), was used, and a P value of <.05 was considered significant. The funders played no role in the design, conduct, or reporting of this study. One hundred fifty-six patients were assessed throughout the study period, and of these, 75 were included according to the flowchart shown in Figure 1 . Most patients were men, with a mean age of 53 (SD = 13) years and more than 2 preexisting comorbidities, the most prevalent being obesity, systemic hypertension, and diabetes mellitus (Tab. 1). The occurrence of ICUAW in the first assessment (when patients were awakened in the ICU for weaning from ventilatory support) was 52%, decreasing to 38% on discharge from the ICU and to 13% on hospital discharge. The lengths of stay in the ICU and the hospital, the rates of use of IMV, the time on MV, the time to first leaving bed rest, and the number of physical therapy sessions were higher in patients with ICUAW (Tab. 2). In addition, patients with ICUAW used sedatives, NMBA, antibiotics, corticosteroids, and vasopressors for longer periods; received more renal replacement therapy; were more often in a prone position; remained in deep sedation (Richmond Agitation-Sedation Scale score of −4 or −5) for more days; and had more complications while in the ICU (Tab. 3). As for muscle strength and mobility, patients with ICUAW showed lower results at all times assessed than patients without ICUAW (P < .05). In a multivariable regression analysis, the development of ICUAW was used as a dependent variable, and the independent variables were those that were significant in the univariate analysis but were not found to have a very strong correlation among them and that had been reported in previous studies as risk factors for ICUAW 6, 8, 9 (Simplified Acute Physiology Score III, sepsis, use of aminoglycosides, renal replacement therapy, hyperglycemia, and bed rest time). Bed rest time was the only factor independently associated with ICUAW (relative risk = 1.14; 95% CI = 1.02-1.28; P = .03 for each immobile week). Considering only the patients who were under IMV, the occurrence of ICUAW at ICU discharge was 46.0%, and the following factors were shown to be independently associated: days on bed rest (relative risk = 1.02; 95% CI = 1.00-1.03; P = .01 for each week on rest) and days on corticosteroids (relative risk = 1.01; 95% CI = 1.00-1.03; P = .01). As for the evolution throughout hospitalization, patients with ICUAW were found to have an increase in muscle strength according to the MRC score (Fig. 2a) Regarding mobility, both groups showed an increase in the Perme Score (Fig. 2c) at all assessments (P < .05), suggesting progressively higher levels of mobility. According to the ICU Mobility Scale (Fig. 2d) , both groups had an increase in mobility levels from assessment 1 to assessment 2 (P < .05); however, from assessment 2 to assessment 3, this ICUAW is a frequent complication in patients who are critically ill with COVID- 19 and are admitted to the ICU. Patients with ICUAW had longer ICU stays, hospital stays, and time on MV, received more physical therapy sessions, and had lower levels of strength and mobility upon awakening, at ICU discharge, and at hospital discharge. Several clinical variables to which patients who were critically ill were exposed were associated with ICUAW, but time on bed rest for all patients and the time of use of Several independent risk factors for the development of ICUAW have been identified and described in the literature, but there are still no studies assessing these factors in patients with COVID-19. The severity of the critical illness and the occurrence of sepsis were considered predictive for ICUAW in previous studies 6 ; these data were reinforced by the findings of our study. Hyperglycemia was also a factor associated with ICUAW in the studied population, as already evidenced in studies with clinical and surgical patients admitted to the ICU. 6 Some drugs used to treat patients who are critically ill are associated with ICUAW. In the present study, time on vasopressors, corticosteroids, antibiotics, NMBA, and sedatives was associated with ICUAW. The use of vasoactive drugs and aminoglycosides and the length of time on antibiotics has been reported as a factor associated with ICUAW. [19] [20] [21] [22] As for corticosteroids, a systematic review suggested an association with ICUAW, recommending that exposure to this drug should be reduced. 23 In the treatment of patients who are critically ill with COVID-19, the use of dexamethasone was recommended, as it results in lower mortality in patients who needed oxygen or MV 24 and was, therefore, a treatment used in most patients in the present study. Time on corticosteroids was an independent factor associated with ICUAW in patients who needed IMV. The occurrence of hypoxemic respiratory failure and acute respiratory distress syndrome leads to the need for deep sedation and prolonged use of neuromuscular blocking agents. [1] [2] [3] [4] [5] The association between ICUAW and NMBA, found in the present study, had already been reported by Yang et al in studies in the general population (overall risk = 2.03; 95% CI = 1.22-3.4; I 2 = 72.9%). 6 The use of NMBA associated with deep sedation also tended to increase the risk of ICUAW compared to lighter sedation targets. 25 It is difficult to isolate the direct effects of drugs from the harmful impact of bed rest and inactivity caused by sedation. These associated factors induce severe muscle inactivity with consequent atrophy due to disuse and impaired physical mobility. 26 The need for longer periods of bed rest in patients with COVID-19 has been evidenced by McWillians et al, who reported an average time of 14 days until first mobilization. 18 In the present study, bed rest was a factor independently associated with ICUAW, reinforcing what was evidenced previously in patients who were critically ill. 27 Patients with ICUAW had significant improvement in muscle strength during hospitalization. All patients underwent an intensive rehabilitation program, based on early mobilization and walking, as soon as they showed enough clinical stability for this. The feasibility and effectiveness of rehabilitation measures for patients who were critically ill with COVID-19 during hospitalization were previously reported by McWillianns et al. 18 Mobility in patients with ICUAW, assessed with the Perme Score, was lower at all assessed times, showing the negative impact of ICUAW on the mobility of patients who were critically ill. In the ICU Mobility Scale assessment, however, there was no statistically significant difference between the times of ICU discharge and hospital discharge in patients with ICUAW; still, when the clinical relevance of this finding is analyzed, it becomes significant, since patients could walk from the bed to a chair at ICU discharge and could walk (for at least 5 m) with the help of 1 person at hospital discharge. This study had some limitations. Since this was an exploratory cohort study, it was not possible to determine causality, only the association between factor and outcome. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Clinical course and predictors of 60-day mortality in 239 critically ill patients with COVID-19: a multicenter retrospective study from Wuhan Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study The Use of Analgesia and Sedation in Mechanically Ventilated Patients With COVID-19 Acute Respiratory Distress Syndrome Risk factors for intensive care unit-acquired weakness: A systematic review and meta-analysis An official American Thoracic Society Clinical Practice guideline: the diagnosis of intensive care unit Van den Berghe G. ICU-acquired weakness Neuromuscular dysfunction acquired in critical illness: a systematic review Impact of ICU-acquired weakness on post-ICU physical functioning: a follow-up study Neuromuscular involvement in COVID-19 critically ill patients Intensive care unit acquired muscle weakness in COVID-19 patients Paresis acquired in the intensive care unit: a prospective multicenter study Reference equations for predicting of handgrip strength in Brazilian middle-aged and elderly subjects Perme Intensive Care Unit Mobility Score and ICU Mobility Scale: translation into Portuguese and cross Early prediction of intensive care unitacquired weakness using easily available parameters: a prospective observational study Rehabilitation Levels in Patients with COVID-19 Admitted to Intensive Care Requiring Invasive Ventilation. An Observational Study Impact of Vasoactive Medications on ICU-Acquired Weakness in Mechanically Ventilated Patients Predisposing factors for critical illness polyneuromyopathy in a multidisciplinary intensive care unit Is gentamicin affecting the neuromuscular system of critically ill patients? Aminoglycoside use and intensive care unit-acquired weakness: A systematic review and meta-analysis Dexamethasone in Hospitalized Patients with Covid-19 Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome. Reply Complications of sedation and critical illness Physical complications in acute lung injury survivors: a two-year longitudinal prospective study